Streamline Health announced it will delay its Q3 earnings release and investor conference call to allow the company time to resolve and make appropriate adjustments to its accounting for amortization expenses related to certain software projects. The company is analyzing the need to amend previously filed financial statements as part of its discovery and review process. The company foresees no impact from this adjustment on its revenue, adjusted EBITDA or cash flow in fiscal year 2019 or prior periods. "Our discovery that software projects were not appropriately amortized is unfortunate, but we do not expect that it will have a material impact on revenue, adjusted EBITDA or cash flow," stated Thomas J. Gibson, CFO. "I want to assure our shareholders that we are working diligently to resolve this issue and believe we will do so in short order. The timing of the discovery prevented us from meeting our scheduled earnings release date and investor conference call for our third quarter performance results, which I'm pleased to report were strong across the board. In the third quarter ended October 31, 2019, we generated approximately $5.7 million in revenues producing improved adjusted EBITDA and $2.5 million in bookings." The Company plans to file its Form 10-Q and report its earnings for its third quarter no later than January 9, 2020.

In an interview on CNBC's Mad Money, Nutanix CEO Dheeraj Pandey said: A lot of large companies are thinking about whether they need to own technology... The only way to give customers the freedom they need is through subscriptions... Many companies took an on-premises model and realized they needed to move to a subscription-based model.

Bluebird bio (BLUE) and Bristol-Myers Squibb (BMY) announced updated safety and efficacy results from the ongoing Phase 1 study (CRB-402) of bb21217, an investigational BCMA-targeted chimeric antigen receptor T cell therapy being studied in patients with relapsed/refractory multiple myeloma. The data were presented at the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, Florida. bb21217 is an investigational BCMA-targeted CAR T cell therapy that uses the idecabtagene vicleucel CAR molecule and is cultured with the PI3 kinase inhibitor to enrich for T cells displaying a memory-like phenotype with the intention to increase the in vivo persistence of CAR T cells. "Early data from the CRB-402 study in heavily pre-treated patients (median of six prior lines) with relapsed/refractory multiple myeloma demonstrate the potential for durable responses following bb21217 CAR T cell treatment, with a median duration of response of 11.1 months at the 150 x 106 CAR+ T cell dose level," said David Davidson, M.D., chief medical officer, bluebird bio. "Consistent with the hypothesis underlying the bb21217 program that memory-like phenotype T cells may survive longer in vivo, we have observed durable CAR T cell persistence in evaluable patients with ongoing response at up to 18 months following treatment. We are continuing to recruit additional patients in the study and performing ongoing assessments of the functional persistence of bb21217, as well as its potential correlation to durability of response." "The data of CRB-402 provide additional support that targeting BCMA with a CAR T therapy could be beneficial in treating relapsed/refractory multiple myeloma, particularly for heavily pre-treated patients," said Kristen Hege, M.D., Senior Vice President, Hematology/Oncology and Cell Therapy, Early Clinical Development for Bristol-Myers Squibb. "We have observed durable responses with bb21217 in this study and look forward to further results." "One of the challenges in treating patients with relapsed/refractory multiple myeloma is that they often become resistant to currently available therapies and response durations generally shorten with each subsequent therapy," said presenting author Jesus Berdeja, M.D., Sarah Cannon Center for Blood Cancers, Nashville, Tennessee. "In this heavily-treated patient population, we are encouraged by the results with bb21217 treatment in this ongoing study."

In a regulatory filing, Occidental Petroleum disclosed that its director Jack Moore bought 12.9K shares of common stock on December 6th. The total transaction size was $498K.

In a regulatory filing, Occidental Petroleum disclosed that its director William Klesse bought 10K shares of common stock on December 6th. The total transaction size was $388.2K.

Editas Medicine announced in vivo proof-of-concept data supporting the development of EDIT-301 as a potentially best-in-class, durable medicine to treat sickle cell disease and beta-thalassemia. EDIT-301 is the first experimental medicine in development using Cas12a. The company reported these data today at the 61st Annual Meeting and Exposition of the American Society of Hematology in Orlando, Fla. In this study, when EDIT-301 was infused into NBSGW mice, HbF levels in human red blood cells were increased by approximately 50 percentage points above background at 16 weeks post-engraftment with pancellular distribution and no lineage skewing. These elevated HbF levels were observed after editing with Cas12a which created an editing profile that enriched genomic changes that favored high and persistent HbF levels.

The Trustees of Mesabi Trust (MSB) reported that the Trust has initiated arbitration against Northshore Mining Company and its parent, Cleveland-Cliffs (CLF), the lessee/operator of the leased lands. The arbitration proceeding has been commenced with the American Arbitration Association. The Trust asserts claims concerning the calculation of royalties related to the production, shipment and sale of iron ore, including DR-grade pellets. More particularly, the claims involve the Trust's allegations that the Operator has failed to properly record and calculate royalty amounts during the second and third quarters of 2019. Based on information currently available to the Trust, the Trust seeks an award of damages, along with specific performance and declaratory relief.

Green Plains CEO Todd Becker disclosed in a filing that he had sold 41,957 shares of company stock at an average price of $14.48 per share on December 5. The total transaction value of the sale was $607,328.